In a recent clinical trial, a low dose of aspirin reduced the risk of colon and rectal cancer recurrence by half in patients whose tumors carried a specific genetic mutation.
Just 160 milligrams of aspirin daily—about half a pill of a standard adult tablet—reduced cancer recurrence by around 60 percent in a certain patient subgroup.These patients carried mutations in the PI3K gene, which affects about a third of all colorectal cancer patients.
